Abstracts Archive - Page 359 of 2607 - ACR Meeting Abstracts

Abstract Number: 0768 • ACR Convergence 2024
Addressing Gaps in Polymyalgia Rheumatica: A Systematic Literature Review
Shelley Fritz¹, Angela Degrassi², Kelly Gavigan², Ruohan Hong³, Santiago Munoz Perez², Esteban Rivera⁴, Erik Stone⁵, Laura Stradford⁶, Ambika Vartak², Anne Sydor² and Shilpa Venkatachalam³, ¹Global Healthy Living Foundation, Kalaheo, HI, ²Global Healthy Living Foundation, Upper Nyack, NY, ³Global Healthy Living Foundation, New York, NY, ⁴Global Healthy Living Foundation, Long Island City, NY, ⁵Global Healthy Living Foundation, Upper Nyack, ⁶Global Healthy Living Foundation, Nyack, NY
Background/Purpose: This systematic literature review on polymyalgia rheumatica (PMR) and PMR with giant cell arteritis (GCA) evaluates existing literature on disease burden, management, and treatment…
Abstract Number: 0774 • ACR Convergence 2024
A Multicenter, Randomized, Controlled Trial to Evaluate the Effects of Low-dose Glucocorticoids Compared to Stopping Glucocorticoids to Maintain Remission of Granulomatosis with Polyangiitis: The TAPIR Trial
Peter Merkel¹, Christian Pagnoux², Nader Khalidi³, Ulrich Specks⁴, Curry Koening⁵, Carol Langford⁶, Larry Moreland⁷, Paul Monach⁸, Jason Springer⁹, Shubhasree Banerjee¹, Simon Carette¹⁰, Rennie Rhee¹, Medha Soowamber¹¹, Kenneth Warrington⁴, Renee Borchin¹², Cristina Burroughs¹³, Carol McAlear¹, David Cuthbertson¹³ and Jeffrey Krischer¹³, ¹University of Pennsylvania, Philadelphia, PA, ²Mount Sinai Hospital, Toronto, ON, Canada, ³McMaster University, Hamilton, ON, Canada, ⁴Mayo Clinic, Rochester, MN, ⁵University of Texas Dell Medical School, Austin, TX, ⁶Cleveland Clinic, Moreland Hills, OH, ⁷University of Colorado, Denver, CO, ⁸VA Boston Healthcare System, Boston, MA, ⁹Vanderbilt University Medical Center, Franklin, TN, ¹⁰Mount Sinai Hosptial, Toronto, ON, Canada, ¹¹University of Toronto, Toronto, ON, Canada, ¹²University of South Florida, Tampa, ¹³University of South Florida, Tampa, FL
Background/Purpose: Use of low-dose glucocorticoids to maintain remission in patients with granulomatosis with polyangiitis (GPA) remains controversial. Additionally, there is no consensus on how to…
Abstract Number: 0746 • ACR Convergence 2024
Single-cell RNA-Seq Analysis Reveals Distinct Compositional Characterizations and Transcriptomic Profiles of Macrophages in Takayasu’s Arteritis
Lihong du¹, Chenglong Fang², shang Gao³, zuoguan Chen³ and Yongjun Li³, ¹Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China, ²Department of Rheumatology, Second Affiliated Hospital of Fujian Medical University, Quanzhou, China (People's Republic), ³Department of Vascular Surgery, Beijing Hospital, National Center of Gerontology, Beijing, China
Background/Purpose: Macrophages play key roles in the pathogenesis of various inflammatory vascular diseases, such as Takayasu’s arteritis (TAK) and atherosclerosis. However, limited data on the…
Abstract Number: 0387 • ACR Convergence 2024
Absolute Agreement and Inter-rater Reliability of a Web-based Standardized Scoring Tool for Magnetic Resonance Images from Children with Chronic Nonbacterial Osteomyelitis (CNO) Amongst Radiologists
Farzana Nuruzzaman¹, T. Shawn Sato², Jennifer Stimec³, Ramesh S. Iyer⁴, Andrew Carbert⁵, Joel Paschke⁵, Lauren Potts⁶, Xiaoyue Zhang⁷, Walter Maksymowych⁸, Polly Ferguson⁹ and Yongdong (Dan) Zhao¹⁰, and CARRA CRMO Workgroup, ¹Stony Brook Children's Hospital, Stony Brook, NY, ²University of Iowa, Iowa City, ³Hospital for Sick Children, Toronto, ON, Canada, ⁴Seattle Children's Hospital, Seattle, WA, ⁵CARE Arthritis, Edmonton, AB, Canada, ⁶Artist, Long Beach, CA, ⁷Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, ⁸University of Alberta, Edmonton, AB, Canada, ⁹University of Iowa Carver College of Medicine, Iowa City, IA, ¹⁰University of Washington, Redmond, WA
Background/Purpose: The web-based ChRonic nonbacterial Osteomyelitis Magnetic Resonance Imaging Scoring (CROMRIS) portal was developed to assess specific features of bone and soft tissue inflammation in…
Abstract Number: 0765 • ACR Convergence 2024
Tocilizumab in Extracranial Large-Vessel Giant Cell Arteritis and Takayasu Arteritis: A Multicentric Observational Comparative Study
Carmen Lasa Teja¹, Javier Loricera², Diana Prieto-Peña³, fernando lopez gutierrez⁴, Pilar Bernabéu⁵, Mercedes Freire González⁶, ivan Ferraz-Amaro⁷, Santos Castañeda⁸, Mauricio Mínguez⁹, Beatriz bravo-Mancheño¹⁰, Roser Solans-Laqué¹¹ and Ricardo Blanco-Alonso¹², ¹Hospital Universitario Marqués de Valdecilla, Riotuerto, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, ⁴Rheumatology, madrid, Madrid, Spain, ⁵Rheumatology section, Dr. Balmis General University Hospital-ISABIAL, Alicante, Spain, Alicante, Spain, ⁶Complexo Hospitalario Universitario de A Coruña, La coruna, Galicia, Spain, ⁷Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, ⁸Hospital Universitario de la Princesa, Madrid, Spain, ⁹Hospital San Juan de Alicante, Rheumatology., Alicante, Spain, ¹⁰Hospital Universitario Virgen de las Nieves, Granada, Granada., Spain, ¹¹Internal Medicine Service, Vall d'Hebron Hospital University and Campus, Barcelona, Spain, ¹²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Tocilizumab (TCZ) seems to be effective in large vessel (LV) vasculitis including giant cell arteritis (GCA) and Takayasu arteritis (TAK). LV-GCA phenotype shares some…
Abstract Number: 0761 • ACR Convergence 2024
An Observational Study of Lifetime Prevalence of Thromboembolism Among Patients with Giant Cell Arteritis
Ioannis Koulas¹, Nikolaos Tsaftaridis², Ivana Ilic³, Jack Jnani⁴, Alex Spyropoulos¹ and Lara El Khoury⁵, ¹Feinstein Institutes for Medical Research/Northwell Health, Manhasset, ²Feinstein Institutes for Medical Research/Northwell Health, Manhasset, NY, ³Northwell, Brooklyn, NY, ⁴Department of Medicine/Northwell Health, Manhasset, ⁵Division of Rheumatology/Northwell Health, Great Neck, NY
Background/Purpose: Studies indicating a higher incidence rate of stroke and venous thromboembolism (VTE) among patients with giant cell arteritis (GCA) hint at a possible association between…
Abstract Number: 0769 • ACR Convergence 2024
Baseline Evaluation of Diagnoses and Prescribing Patterns in Polymyalgia Rheumatica
Laura Stradford¹, Shilpa Venkatachalam², Kelly Gavigan³, Angela Degrassi³, Emily Holladay⁴, Fenglong xie⁵, Yujie Su⁶, Shanette Daigle⁷ and Jeffrey Curtis⁸, ¹Global Healthy Living Foundation, Nyack, NY, ²Global Healthy Living Foundation, New York, NY, ³Global Healthy Living Foundation, Upper Nyack, NY, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵University of Alabama at Birmingham; Illumination Health, Birmingham, AL, ⁶Illumination Health, Hoover, AL, ⁷FASTER, Birmingham, AL, ⁸University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Polymyalgia rheumatica (PMR) is a chronic inflammatory rheumatic condition that affects approximately 800,000 people in the U.S., occurring almost exclusively after age 50. Moreover,…
Abstract Number: 0725 • ACR Convergence 2024
Serum Glial Fibrillary Acidic Protein Could Assess Cross-sectional Vasculitis Activity by Reflecting Renal Involvement in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Lucy Eunju Lee¹, Taejun Yoon², Yong-Beom Park² and Sang-Won Lee², ¹Yonsei University, Seoul, South Korea, ²Yonsei University College of Medicine, Seoul, Republic of Korea
Background/Purpose: Glial fibrillary acidic protein (GFAP), an intermediate filament protein produced by astrocytes in the CNS, has been identified as a biomarker for disease activity…
Abstract Number: 0715 • ACR Convergence 2024
Diffuse Alveolar Hemorrhage in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Revisited
Samuel Falde¹, Elif Ediboglu¹, Misbah Baqir¹, Rodrigo Cartin-Ceba², Fernando C. Fervenza¹, Ladan Zand¹, Matthew Koster¹, Kenneth Warrington¹ and Ulrich Specks¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Scottsdale, AZ
Background/Purpose: We sought to characterize the most recent cohort of patients presenting with DAH and AAV and to identify risk factors for respiratory failure and…
Abstract Number: 0381 • ACR Convergence 2024
Two- and 3-Year Outcomes of the Childhood Arthritis and Rheumatology Research Alliance FROST Study of New-onset Systemic JIA Treatment
Timothy Hahn¹, George Tomlinson², Yukiko Kimura³, Vincent Del Gaizo⁴, Carlos Valdes⁵ and Timothy Beukelman⁶, and for the CARRA FROST Investigators, ¹Penn State Childrens Hospital, Hershey, PA, ²University of Toronto, Toronto, ON, Canada, ³Hackensack Meridian School of Medicine, New York, NY, ⁴Childhood Arthritis & Rheumatology Research Alliance (CARRA), Whitehouse Station, NJ, ⁵Genentech, Davie, FL, ⁶University of Alabama at Birmingham, Birmingham, AL

Background/Purpose: The FiRst Line Options for sJIA Treatment (FROST) trial was a prospective observational study designed to compare the effectiveness of 4 Childhood Arthritis and…
Abstract Number: 0786 • ACR Convergence 2024
First Analyses of Transcriptomic Changes in the Skin of SSc Patients upon CD19-targeting CAR T Cell Therapy
Janina Auth¹, Manoj Kumar Selvaraju², Fabian Müller³, Pooja Gupta², Arif Ekici⁴, Carlo Tur¹, Maria Gabriella Raimondo¹, Jörg Distler⁵, Clara Dees⁶, Sara Chenguiti⁶, Melanie Hagen¹, Andreas Wirsching¹, Jule Taubmann⁷, Soraya Kharboutli⁸, Silvia Spoerl⁸, Michael Aigner⁸, Sascha Kretschmann⁸, Ingrid Vasova⁸, Andreas MAckensen⁹, Georg Schett¹⁰ and Christina Bergmann¹¹, ¹Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ²CUBiDA Department (Core Unit Bioinformatics and Data Analysis), UKER and FAU, Erlangen, Germany, ³Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Germany, ⁴Core Unit Next Generation Sequencing, Erlangen, Germany, ⁵Universitätsklinikum Düsseldorf and Heinrich-Heine-Universität Düsseldorf, Duesseldorf, Germany, ⁶Department Internal Medicine III, Erlangen, Germany, ⁷Friedrich-Alexander Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁸Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁹Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ¹⁰Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ¹¹Department Internal Medicine III, Friedrich-Alexander-University (FAU) Erlangen-Nurnber, Frankfurt, Germany
Background/Purpose: CD19-targeting CAR T cells showed remarkable improvements of modified Rodnan skin score in SSc patients within 6 months after treatment and stable reduction afterwards…
Abstract Number: 0584 • ACR Convergence 2024
Effectiveness of Tofacitinib Monotherapy versus Combination Therapy in Patients with Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondylarthritis Registry
Alexis Ogdie¹, Nicole Middaugh², Taylor Blachley², Tran Bourgeois³, You-Li Ling⁴, Rajiv Mundayat⁴, Lara Fallon⁵, Karim Masri⁶ and Philip Mease⁷, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²CorEvitas, LLC, Waltham, MA, ³CorEvitas, Waltham, MA, ⁴Pfizer Inc, New York, NY, ⁵Pfizer Inc, Montreal, QC, Canada, ⁶Pfizer Inc, Collegeville, PA, ⁷Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA
Background/Purpose: Real-world (RW) data on the effectiveness of tofacitinib in patients (pts) with PsA are limited. This study summarized disease activity and pt‑reported outcome measures…
Abstract Number: 0758 • ACR Convergence 2024
Difficult to Treat Takayasu Arteritis: Comparative Efficacy of Colchicine and Tofacitinib
Ravi Kumar¹, Prabhu Vasanth², Ramya Janardhana³, Arvind Ganapati⁴, Abhishek Patil⁵, Avinash Jain⁶, Benzeeta Pinto⁷, Ramesh Jois⁸, Shivraj Padiyar⁹, John Mathew⁹, Vineeta Shobha³, George Joseph² and Ruchika goel⁹, ¹Christian Medical college , Vellore , India, Bangalore, India, ²Christian Medical college , Vellore , India, Vellore, Tamil Nadu, India, ³St. John’s Medical College, Bengaluru , India, Bangalore, India, ⁴Kasturba Medical College, Rheumatology Division, Manipal , India, Vellore, Tamil Nadu, India, ⁵Manipal Hospital, Rheumatology, Bengaluru, India, Bengaluru, India, ⁶SMS Medical College and Hospital, Jaipur ,India, JAIPUR, India, ⁷St. John’s Medical College, Bengaluru , India, Bengaluru, India, ⁸Manipal Hospital ,Rheumatology, Millers Road, Bengaluru, India, Bengaluru, India, ⁹Christian Medical college , Vellore , India, Vellore, India
Background/Purpose: Biologic DMARDs (bDMARDs) are mainstay in management of patients with difficult to treat Takayasu Arteritis (D2TTAK). The cost of long-term biologics is prohibitory in…
Abstract Number: 0756 • ACR Convergence 2024
Effectiveness and Safety of Tocilizumab in the Treatment of Polymyalgia Rheumatica: A Meta-Analysis
Ali Raza Khan¹, Nouman Shafique², Abdul Qadeer¹ and zaigham Shaukat¹, ¹Nishtar Medical University, Multan, Punjab, Pakistan, ²AdventHealth Orlando, Orlando, FL
Background/Purpose: Giant Cell Arteritis (GCA) and Polymyalgia Rheumatica (PMR) are different manifestations of the same disease process. GCA is a vasculitis that affects large and…
Abstract Number: 0622 • ACR Convergence 2024
Translation, Adaptation and Validation of the Brazilian-Portuguese Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) Version: Partial Results from a Single Centre
Clarice Mata Machado, Cristina Lanna, Juliana Garrido, Fabiana Moura and Rosa Telles, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
Background/Purpose: In recent years, several indices of disease activity in SLE have been proposed. The Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) showed a high…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].